Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
710 (USA) · Dr. Silva
consented 2013-07-22
AEs
1
Serious
0
Dropout signal
–
Adverse events
severe
assessed
Severe MYOCARDIAL INFARCTION — outcome: FATAL; onset 2013-08-02 (study day 12.0); relationship: POSSIBLE; serious criteria: hospitalization, death, life-threatening
Data queries
No data queries.